CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines
Conclusions and recommendationsCritical appraisal of the literature provided evidence for the value of comprehensiveCYP2D6 genotyping panels in guiding treatment decisions for non-metastatic ER-positive breast cancer patients. Based on this information, it is recommended that alternatives to standard tamoxifen treatments may be considered inCYP2D6 poor or intermediate metabolizers.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Hormonal Therapy | Hormones | Study | Tamoxifen